

Scientific letter

Combined use of subcutaneous implantable defibrillator with endovenous left bundle branch pacing in a child with hypertrophic cardiomyopathy



Uso combinado de desfibrilador subcutáneo y marcapasos transvenoso con estimulación de rama izquierda en una niña con miocardiopatía hipertrófica

To the Editor,

Hypertrophic cardiomyopathy (HCM) is a primary myocardial disease that is typically transmitted in an autosomal dominant fashion. HCM is characterized by broad heterogeneity in clinical expression. Although conduction disturbance is described in

HCM,¹ the occurrence of high-grade atrioventricular block is unusual in children and represents a clinical decision-making challenge. Here, we report a 12-year-old girl, with HCM and a subcutaneous implantable cardioverter-defibrillator (s-ICD) for a previous aborted cardiac arrest, who subsequently developed syncopal paroxysmal atrioventricular block.

The patient was initially referred to our hospital at the age of 8 years, after a ventricular fibrillation episode that was successfully defibrillated. HCM with left ventricular noncompaction and restrictive physiology had been previously diagnosed at another institution. Septal wall myocardium was mildly thickened, and systolic function was normal; there was no left ventricular outflow tract obstruction and both atria were severely enlarged. Cardiac




Figure 1. A: the patient's resting electrocardiogram. B: intermittent high-grade atrioventricular block in loop recorder.




Figure 2. A: chest X-ray showing both subcutaneous implantable cardioverter-defibrillators and left bundle pacemaker. B: four-chamber echocardiographic view showing the left bundle lead (arrow). C: paced QRS width 108 ms.

catheterization showed an increased left ventricular filling pressure. The patient underwent s-ICD implantation and, after a 4-year follow-up, she has not received any appropriate therapy, under no medical treatment.

There was no family history of HCM or sudden cardiac death. The parents, from Morocco, were first-degree cousins. A genetic test by next-generation sequencing identified the homozygous pathogenic variant Asp778Glu in *MHY7* in the proband.

At the age of 12 years, the patient developed unexplained syncopal attacks, with no arrhythmia recorded in the defibrillator. The resting electrocardiogram remained unchanged (figure 1A), so a subcutaneous loop recorder was implanted, demonstrating an intermittent high-degree atrioventricular block that coincided with the loss of consciousness (figure 1B). A definitive dual chamber endovascular pacemaker implant was decided; through the axillary vein, a lumenless 4-Fr lead was used (Select-Secure model 3830 69 cm, Medtronic Inc., United States) (figure 2A,B) through a fixed preformed sheath (C315 HIS, Medtronic Inc, United States) connected to the digital recording system (Electrophysiology Lab System, United States) in a unipolar configuration for recording the intracavitary signal. After locating the His electrogram, the sheath was advanced 1 to 2 cm in the

apical direction; once there, when a paced QRS with “W” morphology was obtained in lead V₁, the electrode was inserted into the septum with 5 to 6 clockwise turns until the notch in the paced QRS complex migrated toward the end of the QRS wave and the QRS width narrowed. No contrast was injected through the sheath. Excellent pacing parameters (R sensed wave 12 mV with a capture threshold 0.5 Volts at 0.4 ms of impulse width) were obtained; subsequently a 52 cm lead was implanted in the right atrial appendage (figure 2A,B). Total fluoroscopy time was 8 minutes. The pacemaker was finally programmed in AAI-DDD mode. Given the narrow QRS complex with extreme similarity to the patient’s resting electrocardiogram (figure 2C), intraoperative s-ICD electrocardiogram screening showed no failure to identify the paced QRS (3 vectors passed), confirmed 24 hours later. The girl has remained well after 6 months of follow-up, with no syncopal recurrences in New York Heart Association functional class II, no additional malignant ventricular arrhythmias, and optimal pacemaker parameters (R sensed wave 15 mV with a capture threshold 0.75 Volts at 0.4 ms). The ventricular pacing rate was 7%.

Our report describes a child with an aggressive form of HCM with restrictive physiology due to a homozygous mutation in

MHY7. The main novel therapeutic approach we provide is the coexistence of an s-ICD together with endovenous left bundle branch pacing to resolve a complex clinical situation. In our patient, when we decided to implant the ICD for secondary sudden cardiac death prevention, no pacing or antitachycardia treatment was expected to be required; hence, to overcome the risks of intravascular lead failure in a young and growing patient, we selected an s-ICD. Nevertheless, when symptomatic atrioventricular block made pacing unavoidable, the left bundle branch pacing option seemed to offer several potential benefits over a single endovenous ICD system: first, the high rate of adverse events with endovascular ICD generator and leads is well known, especially in young patients²; in addition, left bundle pacing is an emerging technique to deliver a more physiological pattern of ventricular pacing, generating a narrow QRS complex and promoting atrioventricular and intraventricular synchrony, thus avoiding adverse consequences of right ventricle pacing on left ventricular function and with lower thresholds and higher R detection than His bundle pacing.³ Finally, a similar paced QRS to the resting QRS allows correct working of the s-ICD, avoiding a failing in electrocardiogram screening and, thus, reducing the chance of inappropriate therapies.

A challenging situation will appear when the s-ICD battery runs out. One option would be to remove the s-ICD system and insert a transvenous defibrillation electrode with a cardiac resynchronization therapy defibrillator device, as long as the girl's size is close to that of the adult. This would allow us to have only 1 generator placed, enhancing the aesthetic result, as well as to dispose of antitachycardia pacing therapy. However, it would mean another element of interference with the tricuspid valve in a young person.

In summary, the combined use of an s-ICD with a left bundle branch pacemaker may be the optimal choice in certain situations, especially in children, in whom deleterious effects of chronic pacing, as well as adverse events related to endovenous defibrillator leads, are extremely undesirable.

CONFLICTS OF INTEREST

M. Álvarez reports personal fees from Boston Scientific and Medtronic, outside the submitted work. The other authors have nothing to disclose.

Francesca Perin,^{a,b,*} Manuel Molina-Lerma,^{b,c} Juan Jiménez-Jáimez,^{b,c} María del Mar Rodríguez-Vázquez del Rey,^{a,b} Ángeles Ortega,^d and Miguel Álvarez^{b,c}

^a Unidad de Cardiología Pediátrica, Servicio de Pediatría, Hospital Universitario Virgen de las Nieves, Granada, Spain

^b Instituto de Investigación Biosanitaria, ibs.GRANADA, Granada, Spain

^c Unidad de Arritmias, Servicio de Cardiología, Hospital Universitario Virgen de las Nieves, Granada, Spain

^d Unidad de Cardiología Pediátrica, Hospital Universitario Torrecárdenas, Almería, Spain

* Corresponding author:

E-mail address: francescaperin33@gmail.com (F. Perin).

Available online 13 August 2020

REFERENCES

- Barrales-Villa R, Centurión-Inda R, Fernández-Fernández X, et al. Severe cardiac conduction disturbances and pacemaker implantation in patients with hypertrophic cardiomyopathy. *Rev Esp Cardiol*. 2010;63:985–988.
- Janousek J, van Geldorp IE, Krupikova S, et al. Permanent cardiac pacing in children: choosing the optimal pacing site: a multicenter study. *Circulation*. 2013;127:613–623.
- Li Y, Chen K, Dai Y, et al. Left bundle branch pacing for symptomatic bradycardia: Implant success rate, safety, and pacing characteristics. *Heart Rhythm*. 2019;16:1758–1765.

<https://doi.org/10.1016/j.rec.2020.06.021>

1885-5857/

© 2020 Sociedad Española de Cardiología. Published by Elsevier España, S.L.U. All rights reserved.

Prognostic value of indexed pulmonary artery diameter assessed by cardiac magnetic resonance imaging in patients with acute heart failure



Valor pronóstico del diámetro indexado de la arteria pulmonar mediante resonancia magnética cardiaca en pacientes con insuficiencia cardiaca aguda

To the Editor,

Pulmonary hypertension (PH) is often associated with heart failure (HF) and is a known predictor of morbidity and mortality in patients with acute HF (AHF).^{1,2} Invasive measurement of pulmonary pressures is considered the gold standard for the diagnosis of PH but is not routinely performed in patients with HF, and echocardiography-based estimation is the most commonly used noninvasive method. However, PH study by estimating systolic pulmonary arterial pressure (sPAP) on

echocardiography is not always feasible, complicating PH assessment in these patients. When sPAP can be calculated, its values correlate poorly with invasive measurements.³ Consequently, there is increasing interest in the development of other noninvasive imaging indexes to estimate pulmonary arterial pressure. The aim of our study was to evaluate the prognostic value of the indexed pulmonary artery (PA) diameter obtained by cardiac magnetic resonance imaging (cMRI) in patients with AHF.

A total of 1229 patients were admitted to our hospital due to AHF from April 2009 to October 2014. In all, 313 (25%) of these patients were prospectively included if cMRI was performed as part of the etiologic study for HF during hospitalization once they had been stabilized. Bright-blood anatomic sequences were used to measure the indexed PA diameter, and the maximum diameter was calculated for the vessel perpendicular to the longitudinal axis of the common pulmonary artery. Patients were grouped into 4 quartiles according to indexed PA diameter,